Option chain shows key data for BioHarvest Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BioHarvest Sciences.

BioHarvest Sciences (NASDAQ:BHST) Stock, Option Chain

BioHarvest Sciences

BioHarvest Sciences Inc. - Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

BHST

News

Health Care

Market-Moving Exclusives

Exclusives

General

BioHarvest&#39;s olive cell compound, rich in Verbascoside, showed promising results in reducing fat accumulation in liver cells, with a 2026 market launch planned.

EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest&#39;s First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

Tate &amp; Lyle and BioHarvest Sciences partner to develop sustainable and affordable plant-based molecules for food and beverage industry.

EXCLUSIVE: BioHarvest Collaborate With Tate &amp; Lyle To Develop Proprietary Plant-Based Molecules

BioHarvest Sciences Inc

Press Releases

BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024

BioHarvest Launches VINIA SuperFood Functional Tea Line

BioHarvest Sciences Reports Third Quarter 2024 Financial Results

Analyst Ratings

Diamond Equity Research Releases Update Note on BioHarvest Sciences Inc. (NASDAQ: BHST, CNSX: BHSC)

Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients Through Botanical Synthesis Technology

BioHarvest Issues Shareholder Letter and Provides Corporate Update

BioHarvest Announces Appointment of Sharon Malka to Board of Directors

BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18

BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD

BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells

CSE:BHSC

Maxim Group

HC Wainwright & Co.

Comments

BioHarvest Sciences

BioHarvest Sciences (BHST) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga